Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002-2012.
Details
Serval ID
serval:BIB_A1EB69849D41
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002-2012.
Journal
Heart
Working group(s)
AMIS Plus Investigators
Contributor(s)
Lessing P., Hess F., Simon R., Hangartner P., Hufschmid U., Hunziker P., Jeger R., Grädel C., Hornig B., Schönfelder A., Windecker S., Rueff T., Loretan P., Schläpfer H., Roethlisberger C., Evéquoz D., Mang G., Ryser D., Niedermaier G., Kistler W., Droll A., Hongler T., Stäuble S., Freiwald G., Schmid H., Stauffer J., Cook S., Bietenhard K., Gaspoz J., Keller P., Wojtyna W., Oertli B., Schönenberger R., Schmidli M., Federspiel B., Schröpfer D., Weiss E., Weber K., Zender H., Steffen C., Poepping I., Hugi A., Frei J., Koltai E., Pedrazzini G., Erne P., Heimes T., Pagnamenta A., Urban P., Stettler C., Repond F., Widmer F., Heimgartner C., Polikar R., Bassetti S., Iselin H., Giger M., Egger P., Kaeslin T., Frey R., Fischer A., Herren T., Caduff B., Eichhorn P., Neumeier C., Flury G., Girod G., Grêt A., Schönenberger R., Vogel R., Niggli B., Rickli H., Yoon S., Stoller U., Bächli E., Schmidt D., Hellermann J., Graber M., Vontobel H., Eriksson U., Haller A., Fischer T., Peter M., Gasser S., Fatio R., Bertel O., Maggiorini M., Eberli F., Fischler M., Christen S., Buchholz S.
ISSN
1468-201X (Electronic)
ISSN-L
1355-6037
Publication state
Published
Issued date
2014
Volume
100
Number
4
Pages
288-294
Language
english
Notes
Publication types: Comparative Study ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov'tPublication Status: ppublish. Grégoire Girod fait partie de AMIS Plus Investigators.
Abstract
OBJECTIVE: This study aimed to assess the impact of individual comorbid conditions as well as the weight assignment, predictive properties and discriminating power of the Charlson Comorbidity Index (CCI) on outcome in patients with acute coronary syndrome (ACS).
METHODS: A prospective multicentre observational study (AMIS Plus Registry) from 69 Swiss hospitals with 29 620 ACS patients enrolled from 2002 to 2012. The main outcome measures were in-hospital and 1-year follow-up mortality.
RESULTS: Of the patients, 27% were female (age 72.1 ± 12.6 years) and 73% were male (64.2 ± 12.9 years). 46.8% had comorbidities and they were less likely to receive guideline-recommended drug therapy and reperfusion. Heart failure (adjusted OR 1.88; 95% CI 1.57 to 2.25), metastatic tumours (OR 2.25; 95% CI 1.60 to 3.19), renal diseases (OR 1.84; 95% CI 1.60 to 2.11) and diabetes (OR 1.35; 95% CI 1.19 to 1.54) were strong predictors of in-hospital mortality. In this population, CCI weighted the history of prior myocardial infarction higher (1 instead of -0.4, 95% CI -1.2 to 0.3 points) but heart failure (1 instead of 3.7, 95% CI 2.6 to 4.7) and renal disease (2 instead of 3.5, 95% CI 2.7 to 4.4) lower than the benchmark, where all comorbidities, age and gender were used as predictors. However, the model with CCI and age has an identical discrimination to this benchmark (areas under the receiver operating characteristic curves were both 0.76).
CONCLUSIONS: Comorbidities greatly influenced clinical presentation, therapies received and the outcome of patients admitted with ACS. Heart failure, diabetes, renal disease or metastatic tumours had a major impact on mortality. CCI seems to be an appropriate prognostic indicator for in-hospital and 1-year outcomes in ACS patients. ClinicalTrials.gov Identifier: NCT01305785.
METHODS: A prospective multicentre observational study (AMIS Plus Registry) from 69 Swiss hospitals with 29 620 ACS patients enrolled from 2002 to 2012. The main outcome measures were in-hospital and 1-year follow-up mortality.
RESULTS: Of the patients, 27% were female (age 72.1 ± 12.6 years) and 73% were male (64.2 ± 12.9 years). 46.8% had comorbidities and they were less likely to receive guideline-recommended drug therapy and reperfusion. Heart failure (adjusted OR 1.88; 95% CI 1.57 to 2.25), metastatic tumours (OR 2.25; 95% CI 1.60 to 3.19), renal diseases (OR 1.84; 95% CI 1.60 to 2.11) and diabetes (OR 1.35; 95% CI 1.19 to 1.54) were strong predictors of in-hospital mortality. In this population, CCI weighted the history of prior myocardial infarction higher (1 instead of -0.4, 95% CI -1.2 to 0.3 points) but heart failure (1 instead of 3.7, 95% CI 2.6 to 4.7) and renal disease (2 instead of 3.5, 95% CI 2.7 to 4.4) lower than the benchmark, where all comorbidities, age and gender were used as predictors. However, the model with CCI and age has an identical discrimination to this benchmark (areas under the receiver operating characteristic curves were both 0.76).
CONCLUSIONS: Comorbidities greatly influenced clinical presentation, therapies received and the outcome of patients admitted with ACS. Heart failure, diabetes, renal disease or metastatic tumours had a major impact on mortality. CCI seems to be an appropriate prognostic indicator for in-hospital and 1-year outcomes in ACS patients. ClinicalTrials.gov Identifier: NCT01305785.
Keywords
Acute Coronary Syndrome/epidemiology, Acute Coronary Syndrome/therapy, Aged, Comorbidity, Diabetes Mellitus/epidemiology, Female, Follow-Up Studies, Heart Failure/epidemiology, Hospital Mortality/trends, Humans, Incidence, Inpatients, Male, Middle Aged, Myocardial Infarction/epidemiology, Myocardial Revascularization/methods, Prognosis, Prospective Studies, ROC Curve, Registries, Survival Rate/trends, Switzerland/epidemiology
Pubmed
Web of science
Open Access
Yes
Create date
12/08/2014 13:53
Last modification date
20/08/2019 15:07
Usage data
